Navigation Links
S&P Capital IQ to Share Its Views on the Biotech Bull Market During the Next "ETF Analyst Hour"
Date:10/21/2013

NEW YORK, Oct. 21, 2013 /PRNewswire/ -- Biotechnology has been one of the strongest performing industries through the first three quarters of 2013, returning 58.3% versus 18.6% for the S&P 500™ index as of September 30, 2013. On Wednesday, October 23rd at 11am EDT, S&P Capital IQ will host a webinar to discuss the factors that have been driving the biotech bull market and whether it's set to continue its run in the months to come.

This webinar, part of the S&P Capital IQ "ETF Analyst Hour" series, will be titled "Biotech Bull Market: How Long Can It Last?" and will feature Steve Silver, Senior Industry Analyst at S&P Capital IQ, providing an overview of the biotech industry, including the factors that have been contributing to its strong recent performance. Silver will be joined by Todd Rosenbluth, S&P Capital IQ's Director of ETF and Mutual Fund Research, who will share his insights on the pros and cons of biotech-specific ETFs and how much exposure to biotech investors may be able to obtain through more diversified ETFs.

This webinar is the latest in S&P Capital IQ's monthly ETF Analyst Hour series and one hour of CFP continuing education credit is available to attendees. Interested attendees can register here: http://bit.ly/18WZTfc  

Anthony Hohmann, ETF product manager, will moderate the discussion and highlight S&P Capital IQ's ETF holdings-based ranking methodology and model performance to date.

Following the presentation, the ETF research reports for the ETFs discussed will be available to all attendees. The ETF reports are initially published on S&P Capital IQ's MarketScope Advisor platform.

Follow @spmarketscope and #ETFHour during the webinar for up-to-the-second ETF commentary from S&P Capital IQ equity analysts.

About S&P Capital IQ
S&P Capital IQ, a business line of McGraw Hill Financial (NYSE: MHFI), is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities & Exchange Commission.  S&P capital IQ  provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit www.spcapitaliq.com.

Standard & Poor's Financial Services LLC, its affiliates (together, S&P) or their third-party providers do not guarantee the accuracy, completeness or timeliness of any information, including model, software or application, they provide, and are not responsible for errors and omissions (negligent or otherwise), or for the results obtained from the use of such information.  S&P and its third party providers disclaim any and all express or implied warranties. 

The analyses, including ratings, of S&P are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities or make any investment decisions.  Users of ratings or other analyses should not rely on them in making any investment decision.  S&P's opinions and analyses do not address the suitability of any security.  S&P does not act as a fiduciary or an investment advisor, except where registered as such. 

While S&P has obtained information from sources it believes to be reliable, S&P does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives. 
S&P keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of each of these activities. As a result, certain business units of S&P may have information that is not available to other S&P business units. S&P has established policies and procedures to maintain the confidentiality of certain non–public information received in connection with each analytical process.

Research reports provided by S&P Capital IQ or its affiliates are impersonal and not tailored to the needs of any person, entity or group of persons.  S&P Dow Jones Indices does not contribute to or participate in the development of research reports.


'/>"/>
SOURCE S&P Capital IQ
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. The Zacks Analyst Blog Highlights: SPDR Health Care Select Sector Fund, SPDR S&P 500, SPDRS&P Biotech ETF, PowerShares S&P SmallCap Health Care Portfolio and PowerShares Dynamic Biotechnology & Genome Portfolio
2. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
3. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
4. GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
5. Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)
6. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
7. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
8. Nasseo Wins CONNECT Life Sciences Capital Competition and Joins CONNECT Portfolio
9. Unisense FertiliTech A/S Secures an Additional 20 Million USD in New Capital Investment
10. FibeRio® Technology Corporation Announces Strategic Investment Financing Led by SABIC and Aster Capital
11. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):